Single agent

PreclinicalSmall molecule

SShandong Cancer Hospital and Institute

Single agent is one of 7 small molecule programs targeting Oligometastatic. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OligometastaticUnknown status

OligometastaticPreclinical

Unknown status

Competition

Competitive Landscape

6 competitors in Oligometastatic

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 2

1 2

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

1 3

Vepesid

AAvyxa

Phase 2

1 4

Lu-PSMA I&T

MMedical University of Vienna

Phase 2

1 5

Carboplatin/cisplatin

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 2

1 6

Single agent

SShandong Cancer Hospital and Institute

Preclinical

1 7

Rhgm-CSF

Changchun GeneScience Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oligometastatic1 trial

Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients

Unknown status·SShandong Cancer Hospital and Institute·N/A·NCT03489616·45 enrolled

Staphylococcus Aureus Bacteremia1 trial

Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? (SABEDTIO) Clinical Trial

Enrolling by invitation·WWest Virginia University·Approved·NCT07148960·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Single agent. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Single agent compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Single agent. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong Cancer Hospital and Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShandong Cancer Hospital and Institute

Single agent

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oligometastatic1 trial

Staphylococcus Aureus Bacteremia1 trial

References

Drug Info

Quick Facts

Related News